Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Co.'s primary product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells in development for the treatment of Duchenne muscular dystrophy. Co. has also developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. We show 24 historical shares outstanding datapoints in our CATB shares outstanding history coverage, used to compute CATB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CATB market cap history over the course of time is important for investors
interested in comparing CATB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CATB versus a peer is one thing; comparing
CATB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CATB can fluctuate over the course of history.
With this page we aim to empower investors researching CATB by allowing them to research the CATB market cap history. |
Free CATB Email Alerts:
Video: The Importance of Market Cap
